Mineralys Stock Surges 86.43% on $0.43B Trading Volume Ranked 256th in Market Activity as $175M Public Offering Drives Institutional Confidence

On September 2, 2025, Mineralys Therapeutics (MLYS) surged 86.43% with a trading volume of $0.43 billion, marking a 2,866.08% increase from the previous day and ranking 256th in market activity. The stock’s performance aligns with its announced $175 million public offering to fund clinical development of its hypertension drug lorundrostat.

The offering, managed by major underwriters including BofA Securities, Goldman Sachs, and Evercore ISI, underscores institutional confidence in the biopharmaceutical company’s pipeline. Proceeds will cover research, manufacturing, and pre-commercialization efforts for lorundrostat, a selective aldosterone synthase inhibitor targeting treatment-resistant hypertension and related conditions like chronic kidney disease. While the raise signals progress in advancing the drug’s development, it also introduces dilution for existing shareholders, a common challenge for clinical-stage firms.

Analysts highlight the strategic necessity of the capital infusion, given the high costs of late-stage trials. The offering reflects Mineralys’ focus on unmet medical needs, with lorundrostat addressing a significant market opportunity. Institutional backing from top-tier underwriters further validates the company’s therapeutic approach and long-term potential, despite near-term equity dilution concerns.

Backtest results indicate MLYS closed with an 86.43% price increase and a 2,866.08% surge in trading volume on September 2, 2025, achieving a market rank of 256. The data aligns with the company’s public offering announcement and subsequent market reaction.